|
1）Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia: Results of a multicenter randomized trial. Blood. 1993; 82: 3241-9
|
|
|
|
2）Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyeloblastic leukemia: recommendation from an expert panel on behalf of the European LeukemiaNet. Blood. 2009; 113: 1875-91
|
|
|
|
|
3）Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol. 2011; 29: 495-503
|
|
|
|
|
|
4）Sanz MA, Lo-Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000; 96: 1247-53
|
|
|
|
|
|
5）Ohno R, Asou N, Japan Adult Leukemia Study Group. The recent JALSG study for newly diagnosed patients with acute promyelocytic leukemia (APL). Ann Hematol. 2004; 83(spl 1): S77-8
|
|
|
|
|
|
6）Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic torioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997; 89: 3354-60
|
|
|
|
|
|
7）Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001; 19: 3852-60
|
|
|
|
|
|
8）Yanada M, Tsuzuki M, Fujita H, et al. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood. 2013; 121: 3095-102
|
|
|
|
|
|
9）Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010; 116: 3751-7
|
|
|
|
|
|
10）Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Long-term follow up data. J Clin Oncol. 2010; 28: 3866-71
|
|
|
|
|
|
11）Ghavamzaden A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2006; 17: 131-4
|
|
|
|
|
|
12）Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As203 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2004; 101: 5328-35
|
|
|
|
|
|
13）Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2009; 106: 3342-7
|
|
|
|
|
|
14）Estey E, Garcia-Manero G, Ferrajili A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006; 107: 3469-73
|
|
|
|
|
|
15）Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009; 27: 504-10
|
|
|
|
|
|
16）Iland HJ, Bradstock K, Supple SG, et al. All-trans retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012; 120: 1570-80
|
|
|
|
|
|
17）Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013; 369: 111-21
|
|
|
|
|
|
18）Iland HJ, Wei A, Seymour JF. Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care. Best Pract Res Clin Haematol. 2014; 27: 39-52
|
|
|
|
|
|
19）Breccia M, Cicconi L, Lo-Coco F, et al. ATRA+ATO: has a new atandard of care been established in low-risk acute promyelocytic leukemia? Curr Opin Hematol. 2014; 21: 95-101
|
|
|
|
|
|
20）Zhu HH, Wu DP, Jin J, et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol. 2013; 31: 4215-21
|
|
|
|
|
|
21）Kagechika H, Kawachi E, Hashimoto Y, et al. Retinobenzoic acid. 1. Structure-activity relationships of aromatic amides with retinoidal activity. J Med Chem. 1988; 31: 2182-92
|
|
|
|
|
|
22）Ohno R, Ohnishi K, Takeshita A, et al. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan. Leukemia. 1994; 8(spl 3): S64-9
|
|
|
|
|
|
23）Takeshita A, Shinagawa K, Adachi M, et al. Tamibarotene for the treatment of acute promyelocytic leukemia. Expert Opin Orphan Drugs. 2014. in press
|
|
|
|
|